SCIENCE
Publications & presentations
.png)
Gordon Research Conference on Induced Proximity Modalities and Therapeutics
June 24, 2026
Interdict’s CEO Larry Hamann presents today at the inaugural 2026 Gordon Research Conference on Induced Proximity Modalities and Therapeutics: "Context-Dependent Translation Inhibition to Address Historically Intractable Therapeutic Targets in Oncology and Neurodegeneration"
Dangerous Ideas in Drug Development: Small molecule protein inhibition with Interdict Bio
June 14, 2026
Interdict's CEO Larry Hamann joins Professor Anthony Joshua (Kinghorn Cancer Centre, St. Vincent's Hospital, Sydney) on his podcast series 'Dangerous Ideas in Drug Development' to share updates and progress for our lead program that is in clinical development
View presentation
22nd Annual Industry/Academia Precision Oncology & RadMed Symposium
June 11, 2026
Interdict's CEO Larry Hamann presents today at the 22nd Annual Industry/Academia Precision Oncology & RadMed Symposium: "Exploiting the Achilles Heel of Historically Undruggable MYC through Small Molecule Mediated Context-Dependent Translation Inhibition"
Context-dependent translation inhibition as a cancer therapeutic modality
February 24, 2026
Interdict announces the proof-of-concept study characterizing context-dependent human translation inhibitors, called Interdictors™, as a novel cancer therapeutic modality is now published and available as open access in Nature Communications
View publication
Drug Hunter Flash Talk - Sequence-Selective Translation Inhibition: A Novel Small Molecule Therapeutic Modality
September 11, 2025
Interdict's CEO Larry Hamann presents today at the Drug Hunter Flash Talk series an update on the development of interdictors as sequence-selective translation inhibitors
View presentation
Sequence-Selective Translation Inhibition as a Novel, Proximity-Based Cancer Therapeutic Modality
May 30, 2025
Interdict’s CEO Larry Hamann presents today at the Dana Farber Targeted Degradation Webinar Series an overview of our scientific platform and pipeline efforts
View presentation
Context-Dependent Translation Inhibition as a Novel Cancer Therapeutic Modality
January 9, 2025
Interdict releases proof-of-concept pre-print study demonstrating the ability to design, synthesize, and characterize context-dependent human translation inhibitors, called Interdictors™, as a novel cancer therapeutic modality
View publication